Causaly vs Alan

Alan has a disclosed valuation of $5.8B, while Causaly's valuation is not publicly available, making a direct size comparison difficult. Alan employs 500-1000 people.

Alan has raised more in total funding at $750M, compared to Causaly's $66M — a gap of $684M. Combined, the two companies have completed 6 known funding rounds.

Alan leads with an Awaira Score of 83/100, while Causaly sits at 45/100. That 38-point gap reflects real differences in funding, scale, and traction — it's not a vanity metric.

Causaly was founded by Elias Iosif in 2018. Alan was founded by Jean-Charles Samuelian in 2016. Visit each company's profile on Awaira for a full founder biography.

Causaly: Causaly built a biomedical AI platform that extracts and maps causal relationships from scientific literature at scale, allowing pharmaceutical researchers and scientists to query cause-and-effect relationships across millions of published papers and clinical documents. The platform used a specialised natural language processing system trained to identify causal assertions in biomedical text, producing a structured knowledge graph of disease mechanisms, drug targets, and biological pathways.\n\nThe company was founded in London in 2018 and was acquired by Elsevier, the academic publishing giant, in 2022. The acquisition gave Elsevier an AI layer to sit atop its vast corpus of scientific publications, enabling researchers using ScienceDirect and other Elsevier products to query causal biological knowledge rather than simply searching for documents. Prior to acquisition, Causaly had built a client base among pharmaceutical R&D teams seeking to accelerate literature review and hypothesis generation.\n\nCausaly represented a niche but strategically important segment of the biomedical AI market: causal reasoning and knowledge graph construction. Its acquisition by Elsevier followed a broader trend of academic publishers acquiring AI startups to enhance their platforms, similar to Wiley acquiring Atypon and Springer Nature building AI discovery tools. The company is now integrated into Elsevier Research Intelligence, extending causal AI capabilities to Elsevier institutional subscribers worldwide. Alan: Alan is an AI-powered health insurance platform that combines employer group health insurance products with a digital health companion application, using AI to personalise member health recommendations, streamline claims processing, and provide on-demand access to telehealth and mental health resources. The Paris company holds full insurance carrier status in France, Belgium, and Spain, operating as a licensed insurer rather than a distribution intermediary.\n\nThe company raised approximately $220 million including a Series D round from investors including Temasek, Coatue, and Index Ventures, reaching a valuation of approximately $1.4 billion. Alan reports over half a million members across its markets, covering employees at several thousand companies including Stripe, Spendesk, and Vinted, with strong growth in SME employer sales driven by its digital-first enrolment and claims experience. The Alan app provides members with health navigation, symptom checking, and AI-generated health content in addition to insurance card and claims management functionality.\n\nAlan competes in the European digital health insurance market against traditional mutuals including Malakoff Humanis and AG2R La Mondiale, as well as digital health insurers including Henner and Oscar Health in the US context. Its vertical integration as a licensed insurer combined with a technology platform differentiates it from insurtechs that distribute existing insurer products through digital channels, giving Alan full control over the member experience and claims economics. The company is considered one of the most significant French technology companies building in regulated financial services.

Alan got there first, launching in 2016 — that's 2 years of extra runway. Causaly didn't arrive until 2018. In AI, that kind of head start means more training data, deeper customer relationships, and a bigger talent moat.

Causaly has about 1-50 employees; Alan has about 500-1000. A bigger team usually means more revenue or heavier VC backing, but in AI, small teams can build at massive scale.

Yes — they're direct rivals. Both Causaly and Alan compete in AI Healthcare, targeting many of the same buyers. If you're evaluating one, you should be looking at the other.